Atty Dkt. No.: IRVN-007CON2

USSN: Unassigned

b) measuring any TNF receptor cleaved; and

c) correlating any increase or decrease of the receptor released by the peptide with an ability of the substance to enhance or diminish TRRE activity;

wherein the polypeptide has at least one of the following properties:

i) it comprises at least 10 consecutive amino acid residues encoded in any of SEQ. ID NOs:1-10; or

ii) it comprises at least 15 consecutive amino acids that are at least 80% identical to a sequence encoded in any of SEQ. ID NOs:1-10.

34. The screening method of claim 33, wherein the polypeptide has at least one of the following properties:

i) it comprises at least 10 consecutive amino acid residues contained in SEQ. ID NOs: 147-149, 151, or 153-154; or

ii) it comprises at least 15 consecutive amino acids that are at least 80% identical to a sequence contained in SEQ. ID NOS: 147-149, 151, or 153-154.--

No new matter is introduced by these amendments.